Valve designs for left ventricular conduits

Information

  • Patent Grant
  • 7011095
  • Patent Number
    7,011,095
  • Date Filed
    Wednesday, June 18, 2003
    21 years ago
  • Date Issued
    Tuesday, March 14, 2006
    18 years ago
Abstract
Disclosed is a conduit that provides a bypass around a stenosis or occlusion in a coronary artery. The conduit is adapted to be positioned in the myocardium to provide a passage for blood to flow from a heart chamber to a coronary artery, at a site distal to the blockage or stenosis in the coronary artery. The conduit has a one-way valve positioned therein to prevent the backflow of blood from the coronary artery into the heart chamber.
Description
FIELD OF THE INVENTION

This invention relates to apparatus and method for implanting a conduit to allow communication of fluids from one portion of a patient's body to another; and, more particularly, to a blood flow conduit to allow communication from a heart chamber to a vessel or vice versa, and/or vessel to vessel. Even more particularly, the invention relates to a left ventricular conduit and related conduit configurations for controlling the flow of blood through the conduit to achieve bypass of a stenosed or occluded coronary artery.


BACKGROUND OF THE INVENTION

Coronary artery disease is a major problem in the U.S. and throughout the world. Coronary arteries as well as other blood vessels frequently become clogged with plaque, which at the very least impairs the efficiency of the heart's pumping action, and can lead to heart attack, arrhythmias, and death. In some cases, these arteries can be unblocked through noninvasive techniques such as balloon angioplasty. In more difficult cases, a bypass of the blocked vessel is necessary.


In a bypass operation, one or more venous segments are inserted between the aorta and the coronary artery. The inserted venous segments or transplants act as a bypass of the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of blood to the heart. More than 500,000 bypass procedures are performed in the U.S. every year.


Such coronary artery bypass surgery, however, is a very intrusive procedure that is expensive, time-consuming and traumatic to the patient. The operation requires an incision through the patient's sternum (stemotomy), and that the patient be placed on a bypass pump so that the heart can be operated on while not beating. A vein graft is harvested from the patient's leg, and a delicate surgical procedure is required to piece the bypass graft to the coronary artery (anastomosis). Hospital stays subsequent to the surgery and convalescence are prolonged. Furthermore, many patients are poor surgical candidates due to other concomitant illnesses.


As mentioned above, another conventional treatment is percutaneous transluminal coronary angioplasty (PTCA) or other types of angioplasty. However, such vascular treatments are not always indicated due to the type of location of the blockage or stenosis, or due to the risk of emboli.


Thus, there is a need for an improved bypass system that is less traumatic to the patient.


SUMMARY OF THE INVENTION

The preferred embodiments of the present invention address the need in the previous technology by providing a bypass system that avoids the stemotomy and other intrusive procedures normally associated with coronary bypass surgery. These embodiments also free the surgeon from the need to perform multiple anastomoses as is necessary in the current process.


The preferred device provides a conduit or shunt for diverting blood directly from the left ventricle of the heart to a coronary artery, at a point distal to the blockage or stenosis, thereby bypassing the blocked portion of the vessel. The conduit preferably comprises a tube adapted to be positioned in the myocardium and having a one way valve therein. The valve prevents the backflow of blood from the coronary artery into the left ventricle.


The conduit device is delivered through the coronary artery to a position distal the blockage or stenosis. At that position, the coronary artery, the myocardium and the wall of the left ventricle are pierced to provide an opening or channel completely through from the coronary artery to the left ventricle of the heart. The conduit is then positioned in the opening to provide a permanent passage for blood to flow between the left ventricle of the heart and the coronary artery, distal to the blockage or stenosis. The conduit is sized so that one open end is positioned within the coronary artery, while the other open end is positioned in the left ventricle. The hollow lumen of the conduit provides a passage for the flow of blood.


To prevent the backflow of blood from the coronary artery to the left ventricle of the heart, the conduit is provided with a one-way valve. The valve is preferably a windsock type valve, a flapper valve, a bi- or tricuspid valve, a ball valve, a valve formed from the myocardium itself, or a valve that opens and closes in response to the contraction and relaxation of the heart muscle, or in response to the electrical signals in the heart.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a schematic, cross-sectional view of a human heart, showing a conduit in the myocardium of the heart for forming a bypass between the left ventricle and a coronary artery;



FIG. 1B is an enlarged view of the bypass conduit of FIG. 1A;



FIG. 2 is a cross-sectional view of a windsock valve incorporated into a heart conduit in accordance with a preferred arrangement;



FIG. 3 is a perspective view of a flapper valve incorporated into a heart conduit in accordance with a preferred arrangement;



FIG. 4 is a perspective view of a tricuspid valve incorporated into a heart conduit in accordance with the preferred arrangement;



FIGS. 5A–D are cross-sectional views of a valve formed from the myocardium for use in conjunction with a heart conduit in accordance with a preferred arrangement;



FIGS. 6A–B are cross-sectional views of a valve that is activated by the contractions of the heart muscle for use in conjunction with a heart conduit in accordance with a preferred arrangement;



FIG. 7 is a cross-sectional view of a valve that is activated by the electrical signals in the heart muscle for use in conjunction with a heart conduit in accordance with a preferred arrangement;



FIG. 8 is a cross-sectional view of a ball valve incorporated into a heart conduit in accordance with a preferred arrangement;



FIG. 9A–9B are cross-sectional views of a valve with spring mechanisms incorporated into a heart conduit;



FIGS. 9C–9D are cross-sectional views of a valve with a balloon mechanism incorporated into a heart conduit;



FIGS. 9E–9F are cross-sectional views of a valve with an internal motor incorporated into a heart conduit;



FIG. 10A is a partial cross-sectional view of a ball and cage valve incorporated into a heart conduit;



FIG. 10B is a cross-sectional view of a ball valve incorporated into a heart conduit having a narrower distal end;



FIG. 10C is a cross-sectional view of a ball valve incorporated into a heart conduit having a smooth taper.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

As is well known, the coronary artery branches off the aorta and is positioned along the external surface of the heart wall. Oxygenated blood that has returned from the lungs to the heart then flows from the heart to the aorta. Some blood in the aorta flows into the coronary arteries, and the remainder of blood in the aorta flows on to the remainder of the body. The coronary arteries are the primary blood supply to the heart muscle and are thus critical to life. In some individuals, atherosclerotic plaque, aggregated platelets, and/or thrombi build up within the coronary artery, blocking the free flow of blood and causing complications ranging from mild angina to heart attack and death. The presence of coronary vasospasm, also known as “variant angina” or “Prinzmetal's angina,” compounds this problem in many patients.


As used herein, the term “heart chamber” primarily refers to the interior, or lumenal, aspect of the left or right ventricle or the left or right atrium. The term “conduit,” “stent,” and “tube” herein refer to physical structures, preferably primarily artificial, that can be positioned between two or more chambers or vessels, to allow blood flow from one chamber or vessel to another. A “shunt” is any natural or artificial passage between natural channels, such as heart chambers or blood vessels. The conduit in the preferred arrangement can be made of a variety of materials, including various metals, such as nitinol, or plastics.


As used herein, the term “heart wall” comprises any one or more of the following portions or layers of the mammalian heart: the epicardium, myocardium, endocardium, pericardium, interatrial septum, and interventricular septum.


The principles of the present invention are not limited to left ventricular conduits, and include conduits for communicating bodily fluids from any space within a patient to another space within a patient, including any mammal. Furthermore, such fluid communication through the conduits is not limited to any particular direction of flow and can be antegrade or retrograde with respect to the normal flow of fluid. Moreover, the conduits may communicate between a bodily space and a vessel or from one vessel to another vessel (such as an artery to a vein or vice versa). Moreover, the conduits can reside in a single bodily space so as to communicate fluids from one portion of the space to another. For example, the conduits can be used to achieve a bypass within a single vessel, such as communicating blood from a proximal portion of an occluded coronary artery to a more distal portion of that same coronary artery.


In addition, the conduits and related methods can preferably traverse various intermediate destinations and are not limited to any particular flow sequence. For example, in one preferred embodiment of the present invention, the conduit communicates from the left ventricle, through the myocardium, into the pericardial space, and then into the coronary artery. However, other preferred embodiments are disclosed, including direct transmyocardial communication from a left ventricle, through the myocardium and into the coronary artery. Thus, as emphasized above, the term “transmyocardial” should not be narrowly construed in connection with the preferred fluid communication conduits, and other nonmyocardial and even noncardiac fluid communication are preferred as well. With respect to the walls of the heart (and more specifically the term “heart wall”), the preferred conduits and related methods are capable of fluid communication through all such walls including, without limitation, the pericardium, epicardium, myocardium, endocardium, septum, etc.


The bypass which is achieved with certain preferred embodiments and related methods is not limited to a complete bypass of bodily fluid flow, but can also include a partial bypass which advantageously supplements the normal bodily blood flow. Moreover, the obstructions that are bypassed may be of a partial or complete nature, and therefore the terminology “bypass” or “occlusion” should not be construed to be limited to a complete bypass or a complete occlusion but can include partial bypass and partial occlusion as described.


The preferred conduits and related methods disclosed herein can also provide complete passages or partial passages through bodily tissues. In this regard, the conduits can comprise stents, shunts, or the like, and therefore provide a passageway or opening for bodily fluid such as blood. Moreover, the conduits are not necessarily stented or lined with a device but can comprise mere tunnels or openings formed in the tissues of the patient.


The conduits of the present invention preferably comprise both integral or one-piece conduits as well as plural sections joined together to form a continuous conduit. The present conduits can be deployed in a variety of methods consistent with sound medical practice including vascular or surgical deliveries, including minimally invasive techniques. For example, various preferred embodiments of delivery rods and associated methods are disclosed. In one embodiment, the delivery rod is solid and trocar-like. It may be rigid or semi-rigid and capable of penetrating the tissues of the patient and thereby form the conduit, in whole or in part, for purposes of fluid communication. In other preferred embodiments, the delivery rods may be hollow so as to form the conduits themselves (e.g., the conduits are preferably self-implanting or self-inserting) or have a conduit mounted thereon (e.g., the delivery rod is preferably withdrawn leaving the conduit installed). Thus, the preferred conduit device and method for installation is preferably determined by appropriate patient indications in accordance with sound medical practices.


In order to restore the flow of oxygenated blood through the coronary artery, the preferred arrangement provides for the shunting of blood directly from the heart to a site in the coronary artery which is distal the blockage or stenosis.


Although the specification herein will describe the conduit primarily with reference to the left ventricle, the preferred arrangement can be used with any of the four heart chambers, and with any coronary artery, including the left main coronary artery, the right coronary artery, the left anterior descending artery, the left circumflex artery, the posterior descending artery, the obtuse marginal branch or a diagonal branch.


A tunnel or opening is formed through the wall of the coronary artery and the heart wall and into the left ventricle of the heart which lies beneath, or deep to, the coronary artery. A conduit is positioned in the opening to keep it open, and a one-way valve is positioned within the conduit to prevent blood from flowing back into the left ventricle of the heart from the coronary artery.


The conduit may be introduced into the heart wall in a variety of ways, including by a catheter threaded through the femoral artery into the aorta and thence into the left ventricle and, if necessary, the left atrium; or by a catheter threaded through the femoral vein into the inferior vena cava and thence into the night atrium and right ventricle. Alternatively, the conduit may be introduced through a surgical incision in chest wall (thoracotomy) or sternum (sternotomy).


Further details regarding conduits and conduit delivery systems are described in U.S. patent applications entitled DELIVERY METHODS FOR LEFT VENTRICULAR CONDUIT U.S. application Ser. No. 09/368,868, now U.S. Pat. No. 6,261,304; DESIGNS FOR LEFT VENTRICULAR CONDUIT U.S. application Ser. No. 09/369,048, now U.S. Pat. No. 6,290,728; LEFT VENTRICULAR CONDUIT WITH BLOOD VESSEL GRAFT U.S. application Ser. No. 09/369,061, now U.S. Pat. No. 6,254,564; LEFT VENTRICULAR CONDUITS TO CORONARY ARTERIES AND METHODS FOR CORONARY BYPASS U.S. application Ser. No. 90/369,039, now abandoned, and BLOOD FLOW CONDUIT DELIVERY SYSTEM AND METHOD OF USE U.S. application Ser. No. 09/368,644, now U.S. Pat. No. 6,302,892, filed on the same day as the present application, and U.S. Pat. Nos. 5,429,144 and 5,662,124, the disclosures of which are all hereby incorporated by reference in their entirety.


The opening through the heart wall (including endocardium, myocardium, and epicardium) and coronary artery can be formed in a variety of ways, including by knife or scalpel, electrocautery, cryoablation, radiofrequency ablation, ultrasonic ablation, and the like. Other methods will be apparent to those of ordinary skill in the art.


Referring now to FIGS. 1A and 1B, a coronary artery bypass is accomplished by disposing a conduit 12 (FIG. 1B) in a heart wall or myocardium MYO of a patient's heart PH (FIG. 1A). The conduit 12 preferably extends from the left ventricle LV of heart PH to a clogged coronary artery CA at a point downstream of a blockage BL to create a passageway therethrough. Conduit 12 is preferably made of a biocompatible material such as stainless steel or nitinol, although other materials such as Ti, Ti alloys, Ni alloys, Co alloys and biocompatible polymers may also be used. In one embodiment, conduit 12 has a one way valve 14 to allow blood to flow from the left ventricle LV to the coronary artery CA. Although the conduit 12 may elastically deform under the contractive pressure of the heart muscle during systole, the stent remains open to allow blood to pass from the patient's left ventricle LV into the coronary artery CA. During diastole, the blood pumped into coronary artery through passageway is blocked by one-way valve 14 from returning to left ventricle LV.


One embodiment of the preferred arrangement is illustrated in FIG. 2. The valve 10 incorporates a design similar to a windsock. The valve 10 is preferably formed from a biocompatible fabric-like material incorporated during the construction of the conduit 12. The high-pressure blood flow causes the valve 10 to open, while the backflow of blood catches the edges of the valve 10 and causes it to close, stopping the flow. The valve 10 can be positioned anywhere along the length of the conduit 12.


The valve 10 is preferably constructed from a biocompatible and very compliant fabric or other material that is pushed aside by the high forward blood pressure created from the contraction of the heart muscle, but opens to “catch” the back-flow of blood passing back through the conduit 12. The valve 10 is preferably constructed by incorporating the fabric or other material into the conduit 12 directly during its manufacture. This allows the valve 10 and conduit 12 to be introduced as a single unit.


Another embodiment of the preferred arrangement is illustrated in FIG. 3. This valve 15 is a type of “flapper valve” that is built onto the end of the conduit 12 that is positioned in the coronary artery. The high-pressure blood flow opens the flap 15 and the backflow of blood causes the flap 15 to shut. This flap 15 is slightly larger than the conduit 12 inner diameter (ID) to accomplish this action and to ensure a proper seal. The valve 15 is preferably formed from the same material as the conduit 12 and the two are preferably introduced as a single unit. Alternatively, the valve 15 may be attached as a secondary operation once the conduit 12 is in place.


The third embodiment of the valve 16 is illustrated in FIG. 4. This valve 16 is similar to a natural heart valve. A bi- or tricuspid arrangement of semi-circular spheres is forced open by the high-pressure flow and collapses back to prevent backflow of blood through the conduit 12. This valve 16 is preferably made from the same material as the conduit 12, or alternatively, from a thin biocompatible material that is built onto the conduit 12. Preferably, the valve 16 and the conduit 12 are manufactured together and introduced as a single unit. Alternatively, the valve 16 may be attached to the conduit 12 in a secondary operation once the conduit 12 is in place. The valve 16 may be placed at any location along the length of the conduit 12.


A further embodiment of the conduit is illustrated in FIGS. 5A–D. Here, the heart wall, which includes the myocardium MYO, lying between the coronary artery CA and the left ventricle of the heart LV, is cut using known techniques to form a passage through the myocardium MYO. FIG. 5A shows the myocardium MYO after a cut or puncture has been made in it, with a free edge 17 shown at each margin of the cut or puncture. FIG. 5B shows the myocardium MYO after a jagged or irregular surface 19 has been made with a cutting tool in the free edge 17 of the myocardium MYO. Such cutting tools may include knives, scalpels, lasers, radiofrequency probes, and other cutting tools known to those of skill in the art.


As illustrated in FIG. 5C, two conduits, an upper or lower conduit, or a single conduit 18 having upper 18a and lower 18b components, is positioned in the passage. The myocardium MYO is left free between the two edges of the conduit 18 to form the valve 20. FIG. 5D shows that during diastole, the edges or free portions of the myocardium MYO come together, closing the passage through the myocardium MYO. During systole, the free portions of the myocardium MYO can move away from one another as cardiac myofibrils contract, opening the passage through the myocardium MYO, as illustrated in FIG. 5C. Thus, the heart muscle MYO itself can form at least part of the valve 20 in the conduit 18 to prevent the backflow of blood.


In another embodiment, the valve in the conduit may be controlled in response to the contractions of the heart. As illustrated in FIGS. 6A and 6B, two conduits (FIG. 6A), an upper conduit 20 and lower conduit 22, or a single conduit (FIG. 6B) having upper moveable components 20 and lower moveable components 22, are positioned in the passage in the myocardium MYO between the left ventricle LV and the coronary artery CA. The conduit or conduits contain a valve 24, which is normally in a closed position, and an actuator 26, which is adapted to open the valve 24 in the conduit. During diastole, when the heart muscle MYO is relaxed, the two conduits or the two components of the conduit 20, 22 are positioned such that the valve 24 remains closed. During systole, the two conduits or components 20, 22 are brought close together, such that the actuator 26 forces the valve 24 to open and allows for the passage of blood therethrough. Thus, the contractions of the heart muscle MYO control the valve 24 in the conduit to prevent the backflow of blood during part of the cardiac cycle, for example diastole.


The valve 24 may also be controlled by a hydrodynamic or electric pump or motor, which is responsive to the contractions of the heart, causing the valve 24 to open and close in response to various parts of the cardiac cycle.


A further embodiment of the preferred arrangement is illustrated in FIG. 7. In this embodiment, electrical sensors 30 regulate the opening and closing of the valve 32 positioned within the conduit 34. The sensor 30 senses the electrical signals produced in the heart muscle, and causes the valve 32 to open during systole, and to close during diastole. This is accomplished by having an actuator 36 act in response to the electrical signals detected by the sensor 30, to open and close the valve 32. For example, the valve 32 can be biased in a closed position. When the sensor 30 detects the electrical signal that occurs during or immediately precedes systole, e.g., a QRS complex in the electrocardiogram, the sensor 30 signals the actuator 36 to force open the valve 32 and allow for the flow of blood therethrough. During diastole, the sensor 30 signals the actuator 36 to allow the valve 32 to close and prevent any backflow of blood. Alternatively, the valve 32 can be biased in an open position. When the sensor 30 senses diastole, such as through coordination with the P wave or PR interval in the electrocardiogram, or, for example, after the sensor delays for a predetermined time period after the QRS complex occurs in the electrocardiogram, it signals the actuator 36 to close the valve 32 and prevent the backflow of blood.


Another embodiment is illustrated in FIG. 8. This valve 42 is a type of “ball valve” that is built into the conduit 40 that is positioned in the coronary artery. The high-pressure blood flow from the left ventricle LV to the coronary artery CA opens the valve 42 by moving the ball 44 away from the opening 46. The backflow of blood from the coronary artery CA to the left ventricle LV causes the ball 44 to seat against the opening 46, thereby closing the valve 42 and preventing the backflow of blood. The valve 42 and the conduit 40 are preferably introduced as a single unit.


Another embodiment is illustrated in FIGS. 9A and 9B. The conduit 12 has a valve 48 with one or more spring mechanisms 50 within its walls. In diastole (FIG. 9A), bloodflow pressure through the valve is relatively low, and the valve assumes a relatively closed position, impeding the passage of blood through the valve 48. In systole (FIG. 9B), flow pressure through the valve is relatively high, and the valve 48 opens as the spring mechanism 50 contracts, to allow blood to flow through the valve 48.


Instead of a spring mechanism 50, the walls of the conduit 12 can have other mechanisms therein to allow differential flow during various parts of the cardiac cycle. For example, the valve 48 can have a gas- or liquid-filled balloon 52 in its wall, as shown in FIGS. 9C and 9D. This balloon mechanism can contract (FIG. 9D, during systole) or expand (FIG. 9C, during diastole) in response to fluid pressure, to allow the valve 48 to open and close, respectively. Alternatively, the valve 48 can have an internal motor 54, shown in FIGS. 9E and 9F, that opens and closes the valve 48 in response to electrical or mechanical signals from the heart during various parts of the cardiac cycle. For example, as illustrated in FIG. 9E, during diastole, the motor preferably closes the valve 48, and during systole, the motor preferably opens the valve 48.


Another embodiment of the valve mechanism is illustrated in FIG. 10A. The conduit 12 has a ball valve 60 that is of the ball-and-cage variety, for example, like the Starr-Edwards heart valve known to those of skill in the art. This valve 60 typically has a wire or mesh cage 62 with a ball 64 within it. The conduit is positioned within the myocardium MYO. During blood flow from the left ventricle LV to the coronary artery CA, the ball 64 moves toward the apex of the cage 62, permitting blood to flow around the ball 64 and through the conduit 12. During backflow of blood from the coronary artery CA to the left ventricle LV, the ball 64 moves toward the base of the cage 62 and seats thereon, fitting tightly onto the base of the cage 62, and blocking the flow of blood from the coronary artery CA to the left ventricle LV.



FIG. 10B illustrates another embodiment wherein a ball 64 is provided within a conduit 12 that is wider at proximal end 56 facing the left ventricle, and narrower at distal end 58 facing the coronary artery. FIG. 10C illustrates a similar embodiment wherein the conduit 12 has a gradual taper from the proximal end 56 to distal end 58. Like the embodiment of FIG. 10A, during blood flow from the proximal end 56 to distal end 58, the ball 64 moves toward the coronary artery CA to allow blood flow around the ball through the conduit. In one embodiment, the cross-section of the conduit 12 in FIGS. 10B and 10C is noncircular, for example elliptical, to allow blood to flow around the ball 64. During backflow from the coronary artery CA to the left ventricle LV, the ball moves against the base 59 of the conduit to block flow of blood therethrough.


The present vascular conduit and valve system provides significant improvements in the present treatment of blockages and significant stenoses in the coronary artery. Although the invention has been described in its preferred embodiments in connection with the particular figures, it is not intended that this description should be limited in any way.

Claims
  • 1. A method of treating a heart, the method comprising: providing at least one hollow implant defining a lumen and being configured to be positioned in a heart wall between a heart chamber and a coronary vessel, wherein, when the at least one hollow implant is positioned in the heart wall, the lumen at least partially defines a blood flow passage between the heart chamber and the coronary vessel, and wherein the passage is at least partially closable in response to movement of cardiac tissue during diastole so as to at least partially obstruct blood flow therethrough;placing the at least one hollow implant in a heart wall between a heart chamber and a blood vessel; andat least partially obstructing blood flow through the at least one hollow implant in response to movement of cardiac tissue during diastole.
  • 2. The method of claim 1, wherein providing the at least one hollow implant includes providing a hollow tube.
  • 3. The method of claim 1, wherein providing the at least one hollow implant wall includes providing a conduit.
  • 4. The method of claim 1, wherein providing the at least one hollow implant includes providing a stent.
  • 5. The method of claim 1, wherein providing the at least one hollow implant heart wall includes providing two hollow implants.
  • 6. The method of claim 5, wherein placing two hollow implants in the heart wall includes placing the hollow implants in the heart wall such that they are separated from each other.
  • 7. The method of claim 6, wherein a length of each of the hollow implants is less than a thickness of the heart wall.
  • 8. The method of claim 1, further comprising permitting blood flow through the at least one hollow implant during systole.
  • 9. The method of claim 1, wherein placing the at least one hollow implant in the heart wall includes placing the at least one hollow implant in the heart wall between a left ventricle and the blood vessel.
  • 10. The method of claim 1, wherein placing the at least one hollow implant in the heart wall includes placing the at least one hollow implant in the heart wall between the heart chamberand a coronary artery.
  • 11. The method of claim 1, wherein placing the at least one hollow implant in the heart wall includes placing the at least one hollow implant in the heart wall between a left ventricle and a coronary artery.
  • 12. The method of claim 1, wherein the at least one hollow implant is adapted to permit blood to flow from the heart chamber to the blood vessel when the blood flow through the at least one hollow implant is not at least partially obstructed.
  • 13. The method of claim 1, wherein the cardiac tissue includes the heart wall.
  • 14. The method of claim 13, further comprising permitting portions of the heart wall proximate the implant to come together during diastole to at least partially obstruct blood flow through the at least one hollow implant.
  • 15. The method of claim 13, further comprising permitting free portions of the heart wall to come together during diastole to at least partially obstruct the blood flow through the at least one hollow implant.
  • 16. The method of claim 1, further comprising forming at least one irregular surface in the heart wall proximate the passage.
  • 17. The method of claim 16, wherein forming the at least one irregular surface in the heart wall includes one of cutting, lasing, and ablating the heart wall.
  • 18. The method of claim 16, wherein the blood flow through the at least one hollow implant is at least partially obstructed in response to movement of the at least one irregular surface during diastole.
  • 19. The method of claim 1, wherein the blood flow through the at least one hollow implant is fully obstructed in response to movement of the cardiac tissue during diastole.
  • 20. A method of treating a heart, the method comprising: providing at least one hollow implant defining a lumen, the at least one hollow implant being configured to be positioned in a heart wall between a heart chamber and a coronary vessel, wherein, when the at least one hollow implant is positioned in the heart wall, the lumen at least partially defines a blood flow passage between the heart chamber and the coronary vessel, and wherein the passage is at least partially closable by cardiac tissue entering the passage so as to at least partially obstruct blood flow therethrough during at least a portion of a cardiac cycle;placing the at least one hollow implant in a heart wall between a heart chamber and a blood vessel; andduring at least a portion of a cardiac cycle, at least partially obstructing blood flow through the at least one hollow implant with cardiac tissue.
  • 21. The method of claim 20, wherein providing the at least one hollow implant includes providing a hollow tube.
  • 22. The method of claim 20, wherein providing the at least one hollow implant includes placing providing a conduit.
  • 23. The method of claim 20, wherein providing the at least one hollow implant includes providing a stent.
  • 24. The method of claim 20, wherein providing the at least one hollow implant includes providing two hollow implants.
  • 25. The method of claim 24, wherein placing two hollow implants in the heart wall includes placing the hollow implants in the heart wall such that they are separated from each other.
  • 26. The method of claim 25, wherein a length of each of the hollow implants is less than a thickness of the heart wall.
  • 27. The method of claim 20, further comprising permitting blood flow through the at least one hollow implant during systole.
  • 28. The method of claim 20, wherein placing the at least one hollow implant in the heart wall includes placing the at least one hollow implant in the heart wall between a left ventricle and the blood vessel.
  • 29. The method of claim 20, wherein placing the at least one hollow implant in the heart wall includes placing the at least one hollow implant in the heart wall between the heart chamber and a coronary artery.
  • 30. The method of claim 20, wherein placing the at least one hollow implant in the heart wall includes placing the at least one hollow implant in the heart wall between a left ventricle and a coronary artery.
  • 31. The method of claim 30, wherein the at least one hollow implant is adapted to permit blood to flow from the left ventricle to the coronary artery when the blood flow through the at least one hollow implant is not at least partially obstructed.
  • 32. The method of claim 20, wherein the cardiac tissue includes the heart wall.
  • 33. The method of claim 32, wherein portions of the heart wall proximate the implant come together during diastole to at least partially obstruct blood flow through the at least one hollow implant.
  • 34. The method of claim 32, wherein free portions of the heart wall come together during at least a portion of the cardiac cycle to at least partially obstruct the blood flow through the at least one hollow implant.
  • 35. The method of claim 20, further comprising forming at least one irregular surface in the heart wall proximate the passage.
  • 36. The method of claim 35, wherein forming the at least one irregular surface in the heart wall includes one of cutting, lasing, and ablating the heart wall.
  • 37. The method of claim 35, wherein the at least one irregular surface at least partially obstructs the blood flow through the at least one hollow implant during at least a portion of the cardiac cycle.
  • 38. The method of claim 20, wherein at least partially obstructing the blood flow through the at least one hollow implant with the cardiac tissue includes fully obstructing the blood flow through the at least one hollow implant with the cardiac tissue.
  • 39. The method of claim 20, wherein the blood flow through the at least one hollow implant is at least partially obstructed during diastole.
  • 40. A method for treating a heart, comprising: positioning a hollow implant in a heart wall between a heart chamber and a coronary vessel so as to support a blood flow passage between the heart chamber and the coronary vessel, the hollow implant having an interior wall surface defining a lumen; andmoving portions of the interior wall surface relative to each other such that, during diastole, the portions reduce a cross-sectional area of the lumen so as to at least partially obstruct blood flow through the implant.
  • 41. The method of claim 40, wherein the hollow implant is configured such that, when positioned in the heart wall, the lumen has a greater cross-sectional area during systole than during diastole at a location of the portions.
  • 42. The method of claim 40, wherein the hollow implant includes a hollow tube.
  • 43. The method of claim 40, wherein the hollow implant includes a stent.
  • 44. The method of claim 40, wherein positioning the hollow implant includes positioning the hollow implant in the heart wall between a left ventricle and a blood vessel.
  • 45. The method of claim 40, wherein positioning the hollow implant includes positioning the hollow implant in the heart wall between the heart chamber and a coronary artery.
  • 46. The method of claim 40, wherein positioning the hollow implant includes positioning the hollow implant in the heart wall between a left ventricle and a coronary artery.
  • 47. The method of claim 40, further comprising biasing the portions of the interior wall surface toward each other during diastole via a mechanism positioned within the wall of the conduit.
  • 48. The method of claim 47, wherein the mechanism is chosen from springs, inflatable structures, and means responsive to electrical and/or mechanical signals.
  • 49. The method of claim 47, wherein the mechanism is configured to permit the interior wall surface portions to move away from each other during systole.
  • 50. The method of claim 40, wherein other portions of the interior wall surface are substantially immovable such that, during the cardiac cycle, the other portions maintain a substantially constant cross-sectional area of the lumen.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application Ser. No. 60/099,777, filed Sep. 10, 1998.

US Referenced Citations (410)
Number Name Date Kind
3671979 Moulopoulos Jun 1972 A
3858246 Milo Jan 1975 A
3911502 Boretos Oct 1975 A
3926215 Macleod Dec 1975 A
4441215 Kaster Apr 1984 A
4503568 Madras Mar 1985 A
4655773 Grassi Apr 1987 A
4680031 Alonso Jul 1987 A
4733665 Palmaz Mar 1988 A
4769029 Patel Sep 1988 A
4953553 Tremulis Sep 1990 A
4979955 Smith Dec 1990 A
4995857 Arnold Feb 1991 A
5035702 Taherei Jul 1991 A
5135467 Citron Aug 1992 A
5193546 Shaknovich Mar 1993 A
5258008 Wilk Nov 1993 A
5287861 Wilk Feb 1994 A
5330486 Wilk Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5344426 Lau et al. Sep 1994 A
5385541 Kirsch et al. Jan 1995 A
5389096 Aita et al. Feb 1995 A
5397351 Pavcnik Mar 1995 A
5409019 Wilk Apr 1995 A
5411552 Andersen et al. May 1995 A
5423744 Gincheff et al. Jun 1995 A
5423851 Samuels Jun 1995 A
5429144 Wilk Jul 1995 A
5443497 Venbrux Aug 1995 A
5456712 Maginot Oct 1995 A
5456714 Owen Oct 1995 A
5470320 Tiefenbrun et al. Nov 1995 A
5487760 Villafana Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5527337 Stack et al. Jun 1996 A
5554119 Harrison et al. Sep 1996 A
5554185 Block et al. Sep 1996 A
5571215 Sterman et al. Nov 1996 A
5578075 Dayton Nov 1996 A
5593434 Williams Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5618299 Khosravi et al. Apr 1997 A
5655548 Nelson et al. Aug 1997 A
5662124 Wilk Sep 1997 A
5713950 Cox Feb 1998 A
5733267 Toro Mar 1998 A
5755682 Knudson et al. May 1998 A
5758663 Wilk et al. Jun 1998 A
5797933 Snow et al. Aug 1998 A
5807384 Mueller Sep 1998 A
5810836 Hussein et al. Sep 1998 A
5824038 Wall Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5830222 Makower Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5843163 Wall Dec 1998 A
5851232 Lois Dec 1998 A
5855597 Jayaraman Jan 1999 A
5865723 Love Feb 1999 A
5876373 Giba et al. Mar 1999 A
5876419 Carpenter et al. Mar 1999 A
5878751 Hussein et al. Mar 1999 A
5885259 Berg Mar 1999 A
5908028 Wilk Jun 1999 A
5908029 Knudson et al. Jun 1999 A
5922022 Nash et al. Jul 1999 A
5925012 Murphy-Chutorian et al. Jul 1999 A
5931848 Saadat Aug 1999 A
5931868 Gross Aug 1999 A
5935119 Guy et al. Aug 1999 A
5935161 Robinson et al. Aug 1999 A
5935162 Dang Aug 1999 A
5938632 Ellis Aug 1999 A
5944019 Knudson et al. Aug 1999 A
5961548 Schmulewitz Oct 1999 A
5968064 Selmon et al. Oct 1999 A
5968093 Kranz Oct 1999 A
5971993 Hussein et al. Oct 1999 A
5976155 Foreman et al. Nov 1999 A
5976159 Bolduc et al. Nov 1999 A
5976169 Imran Nov 1999 A
5976181 Whelan et al. Nov 1999 A
5976182 Cox Nov 1999 A
5976192 McIntyre et al. Nov 1999 A
5976650 Campbell et al. Nov 1999 A
5979455 Maginot Nov 1999 A
5980533 Holman Nov 1999 A
5980548 Evans et al. Nov 1999 A
5980551 Summers et al. Nov 1999 A
5980552 Pinchasik et al. Nov 1999 A
5980553 Gray et al. Nov 1999 A
5980566 Alt et al. Nov 1999 A
5980570 Simpson Nov 1999 A
5984955 Wisselink Nov 1999 A
5984956 Tweden et al. Nov 1999 A
5984963 Ryan et al. Nov 1999 A
5984965 Knapp et al. Nov 1999 A
5989207 Hughes Nov 1999 A
5989287 Yang et al. Nov 1999 A
5993481 Marcade et al. Nov 1999 A
5993482 Chuter Nov 1999 A
5997525 March et al. Dec 1999 A
5997563 Kretiers Dec 1999 A
5997573 Quijano et al. Dec 1999 A
5999678 Murphy-Chutorian et al. Dec 1999 A
6001123 Lau Dec 1999 A
6004261 Sinofsky et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6007543 Ellis et al. Dec 1999 A
6007575 Samuels Dec 1999 A
6007576 McClellan Dec 1999 A
6010449 Selmon et al. Jan 2000 A
6010530 Goicoechea Jan 2000 A
6017365 Von Oepen Jan 2000 A
6026814 LaFontaine et al. Feb 2000 A
6029672 Vanney et al. Feb 2000 A
6033582 Lee et al. Mar 2000 A
6035856 LaFontaine et al. Mar 2000 A
6036677 Javier, Jr. et al. Mar 2000 A
6036697 DiCaprio Mar 2000 A
6045565 Ellis et al. Apr 2000 A
6053911 Ryan et al. Apr 2000 A
6053924 Hussein Apr 2000 A
6053942 Eno et al. Apr 2000 A
6056743 Ellis et al. May 2000 A
6067988 Mueller May 2000 A
6068638 Makower May 2000 A
6071292 Makower et al. Jun 2000 A
6076529 Vanney et al. Jun 2000 A
6080163 Hussein et al. Jun 2000 A
6080170 Nash et al. Jun 2000 A
6092526 LaFontaine et al. Jul 2000 A
6093166 Knudson et al. Jul 2000 A
6093177 Javier, Jr. et al. Jul 2000 A
6093185 Ellis et al. Jul 2000 A
6095997 French et al. Aug 2000 A
6102941 Tweden et al. Aug 2000 A
6106538 Shiber Aug 2000 A
6110201 Quijano et al. Aug 2000 A
6113630 Vanney et al. Sep 2000 A
6113823 Eno Sep 2000 A
6117165 Becker Sep 2000 A
6120520 Saadat et al. Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6126649 VanTassel et al. Oct 2000 A
6126654 Giba et al. Oct 2000 A
6132451 Payne et al. Oct 2000 A
6139541 Vanney et al. Oct 2000 A
6152141 Stevens et al. Nov 2000 A
6155264 Ressemann et al. Dec 2000 A
6156031 Aita et al. Dec 2000 A
6157852 Selmon et al. Dec 2000 A
6159225 Makower Dec 2000 A
6162245 Jayaraman Dec 2000 A
6165185 Shennib et al. Dec 2000 A
6165188 Saadat et al. Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6171251 Mueller et al. Jan 2001 B1
6182668 Tweden et al. Feb 2001 B1
6186972 Nelson et al. Feb 2001 B1
6187034 Frantzen Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6193726 Vanney Feb 2001 B1
6193734 Bolduc et al. Feb 2001 B1
D438618 Solem Mar 2001 S
6196230 Hall et al. Mar 2001 B1
6197050 Eno et al. Mar 2001 B1
6197324 Crittenden Mar 2001 B1
6200311 Danek et al. Mar 2001 B1
6203556 Evans et al. Mar 2001 B1
6213126 LaFontaine et al. Apr 2001 B1
6214041 Tweden et al. Apr 2001 B1
6217527 Selmon et al. Apr 2001 B1
6217549 Selmon et al. Apr 2001 B1
6217575 DeVore et al. Apr 2001 B1
6221049 Selmon et al. Apr 2001 B1
6223752 Vanney et al. May 2001 B1
6224584 March et al. May 2001 B1
6231546 Milo et al. May 2001 B1
6231551 Barbut May 2001 B1
6231587 Makower May 2001 B1
6235000 Milo et al. May 2001 B1
6237607 Vanney et al. May 2001 B1
6238406 Ellis et al. May 2001 B1
6241667 Vetter et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6248112 Gambale et al. Jun 2001 B1
6250305 Tweden Jun 2001 B1
6251079 Gambale et al. Jun 2001 B1
6251104 Kesten et al. Jun 2001 B1
6251116 Shennib et al. Jun 2001 B1
6251418 Ahern et al. Jun 2001 B1
6253768 Wilk Jul 2001 B1
6253769 LaFontaine et al. Jul 2001 B1
6254564 Wilk et al. Jul 2001 B1
6258052 Milo Jul 2001 B1
6258119 Hussein et al. Jul 2001 B1
6261304 Hall et al. Jul 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6283983 Makower et al. Sep 2001 B1
6285903 Rosenthal et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6290709 Ellis et al. Sep 2001 B1
6290719 Garberoglio Sep 2001 B1
6290728 Phelps et al. Sep 2001 B1
6293955 Houser et al. Sep 2001 B1
6302875 Makower et al. Oct 2001 B1
6302892 Wilk Oct 2001 B1
6306125 Parker et al. Oct 2001 B1
6322548 Payne et al. Nov 2001 B1
6330884 Kim Dec 2001 B1
6350248 Knudson et al. Feb 2002 B1
6361519 Knudson et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B1
6363939 Wilk Apr 2002 B1
6375615 Flaherty et al. Apr 2002 B1
6379319 Garibotto et al. Apr 2002 B1
6387119 Wolf et al. May 2002 B1
6390098 LaFontaine et al. May 2002 B1
6395208 Herweck et al. May 2002 B1
6402740 Ellis et al. Jun 2002 B1
6406488 Tweden et al. Jun 2002 B1
6406491 Vanney Jun 2002 B1
6409697 Eno et al. Jun 2002 B1
6409751 Hall et al. Jun 2002 B1
6416490 Ellis et al. Jul 2002 B1
6423089 Gingras et al. Jul 2002 B1
6432119 Saadat Aug 2002 B1
6432126 Gambale et al. Aug 2002 B1
6432127 Kim et al. Aug 2002 B1
6432132 Cottone et al. Aug 2002 B1
6443158 LaFontaine et al. Sep 2002 B1
6447522 Gambale et al. Sep 2002 B1
6447539 Nelson et al. Sep 2002 B1
6454760 Vanney Sep 2002 B1
6454794 Knudson et al. Sep 2002 B1
6458092 Gambale et al. Oct 2002 B1
6458140 Akin et al. Oct 2002 B1
6458323 Boekstegers Oct 2002 B1
6464709 Shennib et al. Oct 2002 B1
6475226 Belef et al. Nov 2002 B1
6475244 Herweck et al. Nov 2002 B1
6482220 Mueller Nov 2002 B1
6491689 Ellis et al. Dec 2002 B1
6491707 Makower et al. Dec 2002 B1
6508825 Selmon et al. Jan 2003 B1
6511458 Milo et al. Jan 2003 B1
6514217 Selmon et al. Feb 2003 B1
6514271 Evans et al. Feb 2003 B1
6517527 Gambale et al. Feb 2003 B1
6517558 Gittings et al. Feb 2003 B1
6524323 Nash et al. Feb 2003 B1
6544230 Flaherty Apr 2003 B1
6559132 Holmer May 2003 B1
6561998 Roth et al. May 2003 B1
6565528 Mueller May 2003 B1
6565594 Herweck et al. May 2003 B1
6569145 Shmulewitz et al. May 2003 B1
6569147 Evans et al. May 2003 B1
6575168 LaFontaine et al. Jun 2003 B1
6579311 Makower Jun 2003 B1
6582444 Wilk Jun 2003 B1
6599304 Selmon et al. Jul 2003 B1
6605053 Kamm et al. Aug 2003 B1
6605113 Wilk Aug 2003 B1
6610100 Phelps et al. Aug 2003 B1
6613081 Kim et al. Sep 2003 B1
6616675 Evard et al. Sep 2003 B1
6638237 Guiles et al. Oct 2003 B1
6638247 Selmon et al. Oct 2003 B1
6638293 Makower et al. Oct 2003 B1
6641610 Wolf et al. Nov 2003 B1
6651670 Rapacki et al. Nov 2003 B1
6652540 Cole et al. Nov 2003 B1
6652546 Nash et al. Nov 2003 B1
6655386 Makower et al. Dec 2003 B1
6660003 DeVore et al. Dec 2003 B1
6660024 Flaherty et al. Dec 2003 B1
6669709 Cohn et al. Dec 2003 B1
6685648 Flaherty et al. Feb 2004 B1
6694983 Wolf et al. Feb 2004 B1
6709425 Gambale et al. Mar 2004 B1
6709444 Makower Mar 2004 B1
6719770 Laufer et al. Apr 2004 B1
6726677 Flaherty et al. Apr 2004 B1
6746464 Makower Jun 2004 B1
6774278 Ragheb et al. Aug 2004 B1
6786929 Gambale et al. Sep 2004 B1
6802858 Gambale et al. Oct 2004 B1
6808498 Laroya et al. Oct 2004 B1
6830568 Kesten et al. Dec 2004 B1
6863684 Kim et al. Mar 2005 B1
6881199 Wilk et al. Apr 2005 B1
20010000041 Selmon et al. Mar 2001 A1
20010004683 Gambale et al. Jun 2001 A1
20010004690 Gambale et al. Jun 2001 A1
20010004699 Gittings et al. Jun 2001 A1
20010008969 Evans et al. Jul 2001 A1
20010012924 Milo et al. Aug 2001 A1
20010012948 Vanney Aug 2001 A1
20010014813 Saadat et al. Aug 2001 A1
20010016700 Eno et al. Aug 2001 A1
20010018596 Selmon et al. Aug 2001 A1
20010020172 Selmon et al. Sep 2001 A1
20010025643 Foley Oct 2001 A1
20010027287 Shmulewitz et al. Oct 2001 A1
20010029385 Shennib et al. Oct 2001 A1
20010034547 Hall et al. Oct 2001 A1
20010037117 Gambale et al. Nov 2001 A1
20010037149 Wilk Nov 2001 A1
20010039426 Makower et al. Nov 2001 A1
20010039445 Hall et al. Nov 2001 A1
20010041902 Lepulu et al. Nov 2001 A1
20010044631 Akin et al. Nov 2001 A1
20010047165 Makower et al. Nov 2001 A1
20010047197 Foley Nov 2001 A1
20010049523 DeVore et al. Dec 2001 A1
20010053932 Phelps et al. Dec 2001 A1
20020002349 Flaherty et al. Jan 2002 A1
20020004662 Wilk Jan 2002 A1
20020004663 Gittings et al. Jan 2002 A1
20020007138 Wilk et al. Jan 2002 A1
20020029079 Kim et al. Mar 2002 A1
20020032476 Gambale et al. Mar 2002 A1
20020032478 Boekstegers et al. Mar 2002 A1
20020033180 Solem Mar 2002 A1
20020045928 Boekstegers Apr 2002 A1
20020049486 Knudson et al. Apr 2002 A1
20020058897 Renati May 2002 A1
20020062146 Makower et al. May 2002 A1
20020065478 Knudson et al. May 2002 A1
20020072699 Knudson et al. Jun 2002 A1
20020077566 Laroya et al. Jun 2002 A1
20020077654 Javier, Jr. et al. Jun 2002 A1
20020092535 Wilk Jul 2002 A1
20020092536 LaFontaine et al. Jul 2002 A1
20020095111 Tweden et al. Jul 2002 A1
20020095206 Addonizio et al. Jul 2002 A1
20020100484 Hall et al. Aug 2002 A1
20020111669 Pazienza et al. Aug 2002 A1
20020111672 Kim et al. Aug 2002 A1
20020116044 Cottone, Jr. et al. Aug 2002 A1
20020123698 Garibotto et al. Sep 2002 A1
20020138087 Shennib et al. Sep 2002 A1
20020143285 Eno et al. Oct 2002 A1
20020143289 Ellis et al. Oct 2002 A1
20020144696 Sharkawy et al. Oct 2002 A1
20020161383 Akin et al. Oct 2002 A1
20020161424 Rapacki et al. Oct 2002 A1
20020165479 Wilk Nov 2002 A1
20020165606 Wolf et al. Nov 2002 A1
20020179098 Makower et al. Dec 2002 A1
20020183716 Herweck et al. Dec 2002 A1
20020193782 Ellis et al. Dec 2002 A1
20030015816 Rapacki et al. Jan 2003 A1
20030018379 Knudson et al. Jan 2003 A1
20030044315 Boekstegers Mar 2003 A1
20030045828 Wilk Mar 2003 A1
20030055371 Wolf et al. Mar 2003 A1
20030073973 Evans et al. Apr 2003 A1
20030078561 Gambale et al. Apr 2003 A1
20030100920 Akin et al. May 2003 A1
20030105514 Phelps et al. Jun 2003 A1
20030120195 Milo et al. Jun 2003 A1
20030149474 Becker Aug 2003 A1
20030158573 Gittings et al. Aug 2003 A1
20030181938 Roth et al. Sep 2003 A1
20030191449 Nash et al. Oct 2003 A1
20030195457 LaFontaine et al. Oct 2003 A1
20030195458 Phelps et al. Oct 2003 A1
20030212413 Wilk Nov 2003 A1
20030216678 March et al. Nov 2003 A1
20030216679 Wolf et al. Nov 2003 A1
20030229366 Reggie et al. Dec 2003 A1
20030236542 Makower Dec 2003 A1
20040006298 Wilk Jan 2004 A1
20040015225 Kim et al. Jan 2004 A1
20040019348 Stevens et al. Jan 2004 A1
20040044392 Von Oepen Mar 2004 A1
20040058097 Weder Mar 2004 A1
20040059280 Makower et al. Mar 2004 A1
20040073157 Knudson et al. Apr 2004 A1
20040073238 Makower Apr 2004 A1
20040077987 Rapacki et al. Apr 2004 A1
20040077988 Tweden et al. Apr 2004 A1
20040077990 Knudson et al. Apr 2004 A1
20040088042 Kim et al. May 2004 A1
20040106931 Guiles et al. Jun 2004 A1
20040113306 Rapacki et al. Jun 2004 A1
20040118415 Hall et al. Jun 2004 A1
20040122318 Flaherty et al. Jun 2004 A1
20040122347 Knudson et al. Jun 2004 A1
20040133154 Flaherty et al. Jul 2004 A1
20040133225 Makower Jul 2004 A1
20040147869 Wolf et al. Jul 2004 A1
20040158143 Flaherty et al. Aug 2004 A1
20040167444 Laroya et al. Aug 2004 A1
20040168691 Sharkawy et al. Sep 2004 A1
20040186507 Hall et al. Sep 2004 A1
20040186557 Gambale et al. Sep 2004 A1
20040186587 Ahern Sep 2004 A1
20040219180 Gambale et al. Nov 2004 A1
20040220598 Bolduc et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040236418 Stevens Nov 2004 A1
20050004505 Phelps et al. Jan 2005 A1
20050004558 Gambale et al. Jan 2005 A1
20050033220 Wilk et al. Feb 2005 A1
Foreign Referenced Citations (177)
Number Date Country
757647 Aug 1999 AU
0 592 410 Oct 1995 EP
0 732 088 Sep 1996 EP
0 815 798 Jul 1997 EP
0 829 239 Aug 1997 EP
0 792 624 Sep 1997 EP
0 797 957 Oct 1997 EP
0 797 958 Oct 1997 EP
0 799 604 Oct 1997 EP
0 801 928 Oct 1997 EP
0 836 834 Oct 1997 EP
0 824 903 Feb 1998 EP
0 876 796 May 1998 EP
0 853 921 Jul 1998 EP
0 858 779 Aug 1998 EP
0 876 803 Nov 1998 EP
0 888 750 Jan 1999 EP
0 895 752 Feb 1999 EP
0 903 123 Mar 1999 EP
0 904 745 Mar 1999 EP
0 934 728 Aug 1999 EP
0 955 017 Nov 1999 EP
0 955 019 Nov 1999 EP
0 962 194 Dec 1999 EP
1 020 166 Jul 2000 EP
1 027 870 Aug 2000 EP
1 088 564 Apr 2001 EP
1 097 676 May 2001 EP
1 166 721 Jan 2002 EP
0 959 815 Dec 2002 EP
1 112 097 Jun 2003 EP
0 954 248 Sep 2004 EP
1 115 452 Nov 2004 EP
1 477 202 Nov 2004 EP
1 107 710 Dec 2004 EP
1 484 081 Dec 2004 EP
1 516 599 Mar 2005 EP
2 316 322 Feb 1998 GB
4-505866 Oct 1992 JP
9846119 Oct 1988 WO
WO 9014804 Dec 1990 WO
WO 9416629 Aug 1994 WO
WO 9632972 Oct 1996 WO
WO 9635469 Nov 1996 WO
WO 9639962 Dec 1996 WO
WO 9639964 Dec 1996 WO
WO 9639965 Dec 1996 WO
WO 9639965 Dec 1996 WO
9713463 Apr 1997 WO
9713471 Apr 1997 WO
WO 9718768 May 1997 WO
9727893 Aug 1997 WO
9727897 Aug 1997 WO
9727898 Aug 1997 WO
9732551 Sep 1997 WO
WO 9741916 Nov 1997 WO
WO 9743961 Nov 1997 WO
WO 9802099 Jan 1998 WO
WO 9803118 Jan 1998 WO
9806356 Feb 1998 WO
9808456 Mar 1998 WO
9810714 Mar 1998 WO
9816161 Apr 1998 WO
WO 9819607 May 1998 WO
WO 9819625 May 1998 WO
9825549 Jun 1998 WO
WO 9824373 Jun 1998 WO
WO 9825533 Jun 1998 WO
WO 9838916 Sep 1998 WO
WO 9838925 Sep 1998 WO
WO 9838939 Sep 1998 WO
WO 9838941 Sep 1998 WO
WO 9839038 Sep 1998 WO
9846115 Oct 1998 WO
WO 9844869 Oct 1998 WO
WO 9849964 Nov 1998 WO
WO 9853759 Dec 1998 WO
WO 9855027 Dec 1998 WO
WO 9857590 Dec 1998 WO
WO 9857591 Dec 1998 WO
WO 9857592 Dec 1998 WO
9908624 Feb 1999 WO
WO 9907296 Feb 1999 WO
9917683 Apr 1999 WO
WO 9915220 Apr 1999 WO
WO 9917671 Apr 1999 WO
9921490 May 1999 WO
9925273 May 1999 WO
WO 9921510 May 1999 WO
WO 9922655 May 1999 WO
WO 9922658 May 1999 WO
WO 9927985 Jun 1999 WO
9936000 Jul 1999 WO
9936001 Jul 1999 WO
WO 9932051 Jul 1999 WO
WO 9935977 Jul 1999 WO
WO 9935979 Jul 1999 WO
WO 9935980 Jul 1999 WO
WO 9937218 Jul 1999 WO
9938459 Aug 1999 WO
9940868 Aug 1999 WO
WO 9940853 Aug 1999 WO
WO 9940963 Aug 1999 WO
9948545 Sep 1999 WO
WO 9944524 Sep 1999 WO
WO 9947071 Sep 1999 WO
WO 9947078 Sep 1999 WO
WO 9948427 Sep 1999 WO
WO 9948549 Sep 1999 WO
9949793 Oct 1999 WO
9949910 Oct 1999 WO
9951162 Oct 1999 WO
9953863 Oct 1999 WO
WO 9949910 Oct 1999 WO
WO 9955406 Nov 1999 WO
9960941 Dec 1999 WO
9962430 Dec 1999 WO
0009195 Feb 2000 WO
WO 0009195 Feb 2000 WO
0012029 Mar 2000 WO
0015146 Mar 2000 WO
0015147 Mar 2000 WO
0015148 Mar 2000 WO
0015149 Mar 2000 WO
0015275 Mar 2000 WO
WO 0010623 Mar 2000 WO
WO 0013722 Mar 2000 WO
WO 0016848 Mar 2000 WO
0021436 Apr 2000 WO
0021461 Apr 2000 WO
0021463 Apr 2000 WO
WO 0018302 Apr 2000 WO
WO 0018323 Apr 2000 WO
WO 0018325 Apr 2000 WO
WO 0018326 Apr 2000 WO
WO 0018331 Apr 2000 WO
WO 0018462 Apr 2000 WO
0024449 May 2000 WO
0033725 Jun 2000 WO
WO 0035376 Jun 2000 WO
WO 0036997 Jun 2000 WO
0041632 Jul 2000 WO
0041633 Jul 2000 WO
WO 0043051 Jul 2000 WO
0045711 Aug 2000 WO
0048530 Aug 2000 WO
WO 0045886 Aug 2000 WO
WO 0049952 Aug 2000 WO
WO 0049954 Aug 2000 WO
WO 0049956 Aug 2000 WO
0056387 Sep 2000 WO
WO 0054660 Sep 2000 WO
WO 0054661 Sep 2000 WO
WO 0056224 Sep 2000 WO
WO 0056225 Sep 2000 WO
WO 0056387 Sep 2000 WO
0066007 Nov 2000 WO
0066009 Nov 2000 WO
0066035 Nov 2000 WO
0071195 Nov 2000 WO
WO 0069345 Nov 2000 WO
WO 0069504 Nov 2000 WO
0110340 Feb 2001 WO
0110341 Feb 2001 WO
0110347 Feb 2001 WO
0110348 Feb 2001 WO
0110349 Feb 2001 WO
WO 0108566 Feb 2001 WO
WO 0108602 Feb 2001 WO
WO 0110350 Feb 2001 WO
WO 0117440 Mar 2001 WO
WO 0126562 Apr 2001 WO
WO 0149187 Jul 2001 WO
WO 0154625 Aug 2001 WO
WO 0170133 Sep 2001 WO
WO 0202163 Jan 2002 WO
WO 0202168 Jan 2002 WO
Related Publications (1)
Number Date Country
20030216679 A1 Nov 2003 US
Provisional Applications (1)
Number Date Country
60099777 Sep 1998 US
Continuations (1)
Number Date Country
Parent 09368393 Aug 1999 US
Child 10463798 US